Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Payables (2016 - 2025)

Coherus Oncology's Payables history spans 13 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, Payables fell 65.16% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, down 65.16%, while the annual FY2025 figure was $9.9 million, 65.16% down from the prior year.
  • Payables for Q4 2025 was $9.9 million at Coherus Oncology, down from $24.9 million in the prior quarter.
  • Across five years, Payables topped out at $126.7 million in Q3 2021 and bottomed at $9.9 million in Q4 2025.
  • The 5-year median for Payables is $28.9 million (2023), against an average of $39.9 million.
  • The largest annual shift saw Payables skyrocketed 956.59% in 2021 before it tumbled 92.17% in 2022.
  • A 5-year view of Payables shows it stood at $16.2 million in 2021, then fell by 28.67% to $11.5 million in 2022, then surged by 205.56% to $35.2 million in 2023, then dropped by 19.2% to $28.5 million in 2024, then tumbled by 65.16% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Payables are $9.9 million (Q4 2025), $24.9 million (Q3 2025), and $37.6 million (Q2 2025).